Correlation diagram of each parameter in each group. by Neng Pan (5262032)

Subjects:

Recruitment process. by Neng Pan (5262032)

Subjects:

Comparison of post-experimental outcome measures. by Neng Pan (5262032)

Subjects:

Significant cholesterol genes arranged by day. by Katherine M. Peterson (19746455)

“…Scatter plots of the RNASeq DESeq results, P-value vs. Fold Change for each sample day, arranged chronologically. …”

Average stability values (mean ± standard deviation) and statistical results. by Hyung Suk Yang (20442438)

Subjects:

Individual stability values for different gait events under various conditions. by Hyung Suk Yang (20442438)

Subjects:

Dynamic stability based on the Feasible Stability Region (FSR). by Hyung Suk Yang (20442438)

Subjects:

Spatial dry and wet side fitting of the TS-NDVI characteristics for different time periods in the Santun River Irrigation Area: (a) 2006/05; (b) 2007/04; (c) 2008/10; (d) 2009/08;... by Yuxin Wei (11510974)

Loss of <i>Rab23</i> decreases ciliation in MEFs and Tbr1 + intermediate progenitors. by Wan Ying Leong (22075947)

Differential expression patterns and functional gene groups associated with SARS-CoV-2 viral load across serially collected samples. by Vasanthi Avadhanula (259546)

Differential expression patterns and functional gene groups associated with SARS-CoV-2 infection of nose organoids. by Vasanthi Avadhanula (259546)

“…<b>(c)</b> Similar to part b, but for genes decreased with SARS-CoV-2 infection. <b>(d)</b> Selected significantly enriched GO terms ⁴¹ within the genes over-expressed with SARS-CoV-2 infection in HNO204 (p<0.05, t-test). …”

Genes correlated with SARS-CoV-2 viral load over time are similarly expressed in independent datasets of SARS-CoV-2 infected lung and upper airway cells. by Vasanthi Avadhanula (259546)

Weekly aerobic exercise volume over time for the DHA and placebo groups combined (n  by Claire M. Douglas (21238238)

Subjects:

Weekly resistance training frequency over time for the DHA and placebo groups combined (n  by Claire M. Douglas (21238238)

Subjects:

Quality of life scores at baseline (week 0) and end of chemotherapy (week 18) in the DHA and placebo groups. by Claire M. Douglas (21238238)

Subjects:

Participant demographic and clinical characteristics. by Claire M. Douglas (21238238)

Subjects:

Quality of life scores at baseline (week 0) and the end of chemotherapy (week 18) in participants that met (≥ 150 minutes/week) or did not meet (< 150 minutes/week) WHO’s aerobic e... by Claire M. Douglas (21238238)

Subjects:

Flow of participants through the DHA WIN RCT. Abbreviations: Docosahexaenoic acid (DHA), Docosahexaenoic acid for Women with Breast Cancer in the Neoadjuvant Setting (DHA WIN), ran... by Claire M. Douglas (21238238)

Subjects:

Quality of life scores at baseline (week 0) and the end of chemotherapy (week 18) in participants that met (≥ 2 times/week) or did not meet (< 2 times/week) WHO’s resistance traini... by Claire M. Douglas (21238238)

Subjects:

Voxel-based whole-brain analysis shows regional and dose-dependent effects of netoglitazone in decreasing plaque count. by Francesca Catto (21253435)

“…Additionally, the plots on the right side display the average plaque count across the cohorts. …”